

**WAGO 2026 Annual Meeting**  
**June 18-20, 2026**  
**Napa, CA**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
<b>Planning Disclosures</b>				
Beavis, MD, MPH	Anna	Planner/ Moderator	Nothing to Disclose	
Bohn, MD	Jacqueline	Planner/ Moderator	Nothing to Disclose	
Cham, MD, MS	Stephanie	Planner/ Moderator	Nothing to Disclose	
Chase, MD	Dana	Planner/ Moderator	AbbVie; AstraZeneca; Corcept; Eisai, GSK; Merck; Pfizer	Consultant (AbbVie; AstraZeneca; Corcept; GSK; Merck) Speaker Honoraria (AbbVie; AstraZeneca; Eisai; GSK; Pfizer) Advisor (AstraZeneca; Corcept; Eisai) Research Grant (GSK; Merck)
Cohen, MD, FACOG, FACS	Joshua	Planner/ Moderator	Corcept; AstraZeneca	Advisor
Fuh, MD	Katherine	Planner	Corcept; Merck; Incyclix; AstraZeneca; GSK	Advisor Leadership and Advisory Roles
Hillman, MD	Tyler	Planner/ Moderator	Nothing to disclose	
How, MD	Jeff	Planner	AstraZeneca; GSK	Research funding to institution
Lazo, MD	Isabel	Planner/ Moderator	Nothing to disclose	
McHale, MD	Micheal	Planner	Eisai, Ethicon	Consultant
Meyer, MD	Larissa	Planner/ Moderator	AbbVie; AstraZeneca; Bristol Myers Squibb; Crispr Therapeutics; Denali; Johnson & Johnson; Merck	Consultant (AbbVie) Research Grant (AstraZeneca; Merck) Ownership Interest/Stocks (Bristol Myers Squibb; Crispr Therapeutics; Denali; Johnson & Johnson)

## FACULTY DISCLOSURE INFORMATION

Pham, MD	Melissa	<b>Planner/ Moderator</b>	Nothing to Disclose	
Richardson, MD	Debra	<b>Planner</b>	AstraZeneca; Corcept; Incyclix; Merck; Natera	Advisor
Richardson, MD	Michael	<b>Planner/ Moderator</b>	Nothing to Disclose	
Urban, MD	Renata	<b>Planner</b>	Nothing to Disclose	
Walsh, MD	Christine	<b>Planner</b>	Nothing to Disclose	
Washington, MD	Christina	<b>Planner</b>	Merck; Eisai; Karyopharm	Advisor
Willmott, MD	Lyndsay	<b>Planner/ Moderator</b>	AstraZeneca; Corcept; Pfizer; AbbVie; Merck; GSK; Eisai; Tubulis; Gilead	Speaker Bureau (AstraZeneca; Corcept; Pfizer; AbbVie; Merck; GSK) Advisory Board (GSK; Corcept; Eisai; Tubulis; Gilead)
<b>Speaker Disclosures</b>				
Adjei, MD, MPH	Naomi	<b>Speaker</b>	Nothing to Disclose	
Adkoli, MD	Anusha	<b>Speaker</b>	Nothing to Disclose	
Amma	Asare	<b>Speaker</b>	Nothing to Disclose	
Araujo, MD	Larissa	<b>Speaker</b>	Nothing to Disclose	
Aryasomayajula, MD	Chinmayi	<b>Speaker</b>	Nothing to Disclose	
Benally, MD	Jessica	<b>Speaker</b>	Nothing to Disclose	
Bolten, MD	Katherine	<b>Speaker</b>	Nothing to Disclose	
Chapman, MD	Jocelyn	<b>Speaker</b>	Nothing to Disclose	
Chua, MD	Katherine- Jane	<b>Speaker</b>	Nothing to Disclose	
Currier, PhD, MPH	Jessica	<b>Speaker</b>	Nothing to Disclose	
Do, MD	Anthony	<b>Speaker</b>	Nothing to Disclose	
Falk, MD	Lauren	<b>Speaker</b>	Nothing to Disclose	
Fife, MD	Alexander	<b>Speaker</b>	Nothing to Disclose	
Finch, MD	Lindsey	<b>Speaker</b>	Johnson & Johnson; Kenvue	Ownership Interests/Stocks
Greenberg, MD	Danielle	<b>Speaker</b>	Nothing to Disclose	
Hohnadel, BS	Grace	<b>Speaker</b>	Nothing to Disclose	
Khetan, MD	Varun	<b>Speaker</b>	Nothing to Disclose	
Knisely, MD	Anne	<b>Speaker</b>	Nothing to Disclose	
Lafferty, MD	Joseph	<b>Speaker</b>	Nothing to Disclose	
Lin, MD	Chen-Tan	<b>Speaker</b>	Nothing to Disclose	
Marta, MD	Patrick	<b>Speaker</b>	Nothing to Disclose	
Moghaddam, BS	Sarah	<b>Speaker</b>	Nothing to Disclose	
Mujumdar, MD	Vaidehi	<b>Speaker</b>	Nothing to Disclose	
Murthy, BS	Ananya	<b>Speaker</b>	Nothing to Disclose	
Nasrallah, MD, MPH	Leane	<b>Speaker</b>	Nothing to Disclose	
Perinchery, MD	Malavika	<b>Speaker</b>	Nothing to Disclose	
Pomerantz, MD	Tali	<b>Speaker</b>	Nothing to Disclose	
Portugues, MD MPH	Alexandra	<b>Speaker</b>	Nothing to Disclose	
Ramanan, MD, MS	Prianca	<b>Speaker</b>	Nothing to Disclose	
Rodriguez, PhD, MSW, MPH	Victoria	<b>Speaker</b>	Nothing to Disclose	
Shachar, MD	Eliya	<b>Speaker</b>	Nothing to Disclose	
Shin, MD	Jordan	<b>Speaker</b>	Nothing to Disclose	
Williams, MD	Gracie	<b>Speaker</b>	Nothing to Disclose	
Zhang, MD, MS	Yingao	<b>Speaker</b>	Nothing to Disclose	
Engbert	Holley	<b>Staff</b>	Nothing to disclose	
Rush	Heather	<b>Staff</b>	Nothing to disclose	
Shumaker	Kara	<b>Reviewer/Staff</b>	Nothing to disclose	
Small, MPH	Michelle N	<b>Reviewer/Staff</b>	Nothing to disclose	
Alvarez Secord, MD	Angeles	<b>Reviewer/Edu- Chair</b>	AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ;	Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses

**FACULTY DISCLOSURE INFORMATION**

			GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria Bio	Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL ) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio)
Duska, MD	Linda	<b>Reviewer/ Edu-Co-Chair</b>	Regeneron; Aadi Bioscience; Daiichi Sankyo; Agenus; NX Development Corp	Advisory Board (Regeneron; Aadi Bioscience; Daiichi Sankyo) Data Safety Monitoring -Money to institution (Agenus) NX Development Corp
Blank, MD	Stephanie	<b>Reviewer</b>	American Board of Obstetrics and Gynecology; Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.	Leadership (American Board of Obstetrics and Gynecology) Research Funding (Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.)
Gien, MD	Lilian	<b>Reviewer</b>	Glaxo Smith Kline; Merck; Abbvie; AstraZeneca	Speaker Honoraria (Glaxo Smith Kline; Merck) Advisory Board (Abbvie; AstraZeneca)
Mutch, MD	David	<b>Reviewer</b>	Nothing to disclose	
Zweizig, MD	Susan	<b>Reviewer</b>	Nothing to disclose	